Profound Medical Corp. Opens the Market

TORONTO, June 15, 2015 /CNW/ - Steve Plymale, CEO, Profound Medical Corp.(PRN) joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange to open the market. Profound Medical is a medical device company that has developed a minimally invasive treatment to ablate the prostate gland. Through combining MRI technology with ultrasound thermal energy that is delivered via a transurethral approach, this investigational method of prostate ablative therapy provides accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. Profound Medical Corp. (PRN) commenced trading on TSX Venture Exchange on June 8, 2015.

SOURCE TMX Group Limited

Image with caption: "Steve Plymale, CEO, Profound Medical Corp.(PRN) joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange to open the market. Profound Medical is a medical device company that has developed a minimally invasive treatment to ablate the prostate gland. Through combining MRI technology with ultrasound thermal energy that is delivered via a transurethral approach, this investigational method of prostate ablative therapy provides accurate and precise treatment within the prostate in a short time span, allowing for fast patient recovery. Profound Medical Corp. (PRN) commenced trading on TSX Venture Exchange on June 8, 2015. For more information please visit www.profoundmedical.com. (CNW Group/TMX Group Limited)". Image available at: http://photos.newswire.ca/images/download/20150615_C5943_PHOTO_EN_18074.jpg

For further information: please visit www.profoundmedical.com.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890